Article Details
Retrieved on: 2021-04-12 08:48:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
RedHill Biopharma is set to continue the global Phase II/III study of orally administered opaganib (Yeliva, ABC294640) in people hospitalised with ...
Article found on: www.clinicaltrialsarena.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here